EUVIMEDEUVIMED entdecken
Crossref

The Design of and Rationale for the Effect of Perioperative Inhaled Tiotropium for Patients with Chronic Obstructive Pulmonary Disease in Esophageal Cancer Surgery (EPITOPE): an Open-Label, Randomized, Parallel-Group Study

Akihiko Okamura, Masayuki Watanabe, Satoru Kitazono, Haruka Manoshiro, Emi Kasama, Keita Takahashi, Tasuku Toihata, Reiko Otake, Ryotaro Kozuki, Yu Imamura, Yuko Yamahara, Naoki Ishizuka

European Surgical Research · 2020 · 61 (4-5) · 123-129

DOI: 10.1159/000506512 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Surgical Research, online erschienen am 03.04.2020. Verfasst von Akihiko Okamura und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pneumonia is one of the most frequently occurring complications after esophagectomy and is associated with increased operative mortality. Chronic obstructive pulmonary disease (COPD) is known to be a risk factor for pulmonary complications and operative mortality. However, in COPD patients preparing for esophagectomy, preventive measures against postoperative pneumonia have not yet been discovered. In this study, we evaluate the effect of perioperative inhaled tiotropium, a long-acting, antimuscarinic bronchodilator used in the management of COPD, on patients with COPD who undergo esophageal cancer surgery. Methods/Design: This study investigates the effect of perioperative inhaled tiotropium on patients with COPD who undergo esophagectomy. It is an open-label, randomized controlled trial conducted in a single center (EPITOPE study). A total of 32 enrolled patients are randomly assigned in a 1:1 ratio to either conventional management or inhalation of tiotropium in addition to the conventional management. Patients included in the intervention group receive tiotropium Respimat 5 μg (two inhalations of 2.5 μg) for at least 2 weeks before the esophagectomy. Following the esophagectomy, tiotropium is re-delivered, starting as early as possible and continuing until the postoperative evaluation (between 30 and 44 days after the operation). The primary outcome is the incidence of pneumonia within 30 days after esophagectomy. Secondary outcomes are the incidence of cardiovascular complications within 30 days after esophagectomy, the incidence of any postoperative complications within 30 days after esophagectomy, pulmonary function (preintervention, preoperative, and postoperative), walking distance in the incremental shuttle walking test (preintervention, preoperative, and postoperative), the incidence of adverse events, and mortality within 30 days after esophagectomy.

Discussion

The EPITOPE study is the first pilot study on the effects of perioperative inhaled tiotropium on patients with COPD undergoing esophagectomy. After completing this study, we will plan a multicenter RCT with the appropriate outcomes in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Administration, InhalationEsophageal NeoplasmsEsophagectomyHumansPilot ProjectsPneumoniaPostoperative ComplicationsProspective StudiesPulmonary Disease, Chronic ObstructiveTiotropium BromideRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Chronic obstructive pulmonary diseaseEsophagectomyTiotropium

Substanzen

Tiotropium Bromide

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, masayuki.watanabe@jfcr.or.jp.
  • Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Orthopedic Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Clinical Trial Planning and Management, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Zitieren

APA

Okamura, A., Watanabe, M., Kitazono, S., Manoshiro, H., Kasama, E., Takahashi, K., Toihata, T., Otake, R., Kozuki, R., Imamura, Y., Yamahara, Y., & Ishizuka, N. (2020). The Design of and Rationale for the Effect of Perioperative Inhaled Tiotropium for Patients with Chronic Obstructive Pulmonary Disease in Esophageal Cancer Surgery (EPITOPE): an Open-Label, Randomized, Parallel-Group Study. European Surgical Research, 61(4-5), 123-129. https://doi.org/10.1159/000506512

Vancouver

Okamura A, Watanabe M, Kitazono S, Manoshiro H, Kasama E, Takahashi K, et al. The Design of and Rationale for the Effect of Perioperative Inhaled Tiotropium for Patients with Chronic Obstructive Pulmonary Disease in Esophageal Cancer Surgery (EPITOPE): an Open-Label, Randomized, Parallel-Group Study. European Surgical Research. 2020;61(4-5):123-129. doi:10.1159/000506512

BibTeX
@article{Okamura2020,
  author = {Okamura, Akihiko and Watanabe, Masayuki and Kitazono, Satoru and Manoshiro, Haruka and Kasama, Emi and Takahashi, Keita and Toihata, Tasuku and Otake, Reiko and Kozuki, Ryotaro and Imamura, Yu and Yamahara, Yuko and Ishizuka, Naoki},
  title = {The Design of and Rationale for the Effect of Perioperative Inhaled Tiotropium for Patients with Chronic Obstructive Pulmonary Disease in Esophageal Cancer Surgery (EPITOPE): an Open-Label, Randomized, Parallel-Group Study},
  journal = {European Surgical Research},
  year = {2020},
  volume = {61},
  number = {4-5},
  pages = {123--129},
  doi = {10.1159/000506512}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche